Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study (KGDinrGBM)
Glioblastoma Multiforme
About this trial
This is an interventional treatment trial for Glioblastoma Multiforme focused on measuring ketogenic diet, recurrent glioblastoma, chemotherapy
Eligibility Criteria
Inclusion Criteria:
- Age 18-60
- Karnovsky Performance Score of 60 or more.
- histologically confirmed glioblastoma multiforme, grade 4
- Ability and willingness to signed informed consent form.
- Documented recurrence or progression after surgical resection/debulking, radiation and temozolomide chemotherapy.
- normal function of liver and kidney
Exclusion Criteria:
- Any systemic illness or unstable medical condition that might pose additional risk, including: cardiac, unstable metabolic or endocrine disturbances, renal or liver disease, past history of renal calculi, hyperuricemia, hypercalcemia, mitochondrial disease, known disorder of fatty acid metabolism, porphyria, carnitine deficiency and pancreatitis
- History of uncontrolled hyperlipidemia or hyperglycemia.
- History of human immunodeficiency virus, or hepatitis C
- Pregnancy or breastfeeding
- Inability or unwillingness of subject to give written informed consent
Sites / Locations
- Beijing Tiantan HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Other
ketogenic diet group
Standard diet group
Ketogenic diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were kept more than 2mmol/L during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
Standard diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were recorded during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.